RenovoRx Expands Reach with RenovoCath Approval

RenovoRx ( (RNXT) ) has issued an announcement.

RenovoRx reported its third-quarter 2025 financial results, highlighting approximately $900,000 in year-to-date revenue and a cash position of $10 million. The company is expanding its commercial reach with the RenovoCath device, now approved in 14 cancer centers, and is advancing its Phase III TIGeR-PaC trial, with enrollment completion expected in early 2026. The company aims to leverage its TAMP platform for long-term growth and improve patient outcomes with targeted therapies.

The most recent analyst rating on (RNXT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

Spark’s Take on RNXT Stock

According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.

RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.

To see Spark’s full report on RNXT stock, click here.

More about RenovoRx

RenovoRx is a life sciences company focused on developing innovative targeted oncology therapies. It is commercializing RenovoCath®, an FDA-cleared drug-delivery device, and is engaged in clinical trials and commercialization strategies to integrate its therapeutic drug-delivery approach into standard care.

Average Trading Volume: 565,021

Technical Sentiment Signal: Sell

Current Market Cap: $36.65M

See more data about RNXT stock on TipRanks’ Stock Analysis page.